Providing an Optimized and emPowered Pregnancy for You (PᵌOPPY) Feasibility Study (PᵌOPPY)

July 19, 2023 updated by: Rachel Sinkey, University of Alabama at Birmingham
The P3OPPY Project is one of five projects within the American Heart Association P3 EQUATE Network. The overarching goal of the P3 EQUATE American Heart Association Health Equity Research Network (HERN) is to promote equity in Maternal and Infant Health outcomes by identifying innovative and cost-effective strategies to enhance access to quality health information, care, and experiences during pregnancy, postnatal and postpartum/preconception periods, particularly for Black and under-served populations. Collectively, the investigators will collaborate with pregnant and postpartum individuals and their families, hospitals, and communities to discover ways to reduce racism and social problems that contribute to poor health outcomes.

Study Overview

Detailed Description

Feasibility Study Aims

  1. To assess the feasibility of the digital health (DHI) and community health worker (CHW) interventions by assessing participant acceptance and use of the intervention.
  2. To assess study enrollment to determine appropriateness and usefulness of the inclusion and exclusion criteria to estimate enrollment duration in the planned trial.
  3. To determine the number of prenatal visits and the incidence of some of the maternal and neonatal outcomes (ones with higher prevalence) or surrogate outcomes that will be targeted in the planned factorial design randomized controlled trial. (Data will be collected on all relevant maternal and neonatal outcomes. The randomized feasibility design will allow for effect size estimates of the intervention on the incidence of maternal and neonatal outcomes, which will aid in determining the appropriate target outcomes as well as power calculation of the more definitive trial.)

The PᵌOPPY study is designed to support the American Heart Association's mission to improve maternal/infant health outcomes and address inequities in maternal/infant health care. The promise of digital health and community health worker engagement makes PᵌOPPY interventions potentially transformative, sustainable, and scalable for Non-Hispanic Black mothers and their infants from under-served communities in Alabama and beyond. The objective of this pilot study is to determine if it is feasible to randomize and implement digital health and community health worker interventions.

Design Summary

The investigators will challenge existing care paradigms by testing the effectiveness of integrating innovative platforms into the existing healthcare system, including existing digital health and community health worker programs from within the EQUATE consortium, to eliminate critical barriers to equitable healthcare access. After seeking input from a Community Advisory Board, these interventions will be refined and deployed for pilot testing. Individuals in Non-Hispanic Black communities at the highest risk of adverse pregnancy outcomes which were historically underrepresented in clinical research due to structural racism will be included. The investigative team employs experts across the community, maternal, and infant health continuum.

For this pilot, 40 eligible participants will be randomized, 10 to usual care, 10 to DHI, 10 to CHW, and 10 to DHI + CHW

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Rosylen "Roz" Quinney
  • Phone Number: 205.934.1309
  • Email: p3oppy@uabmc.edu

Study Contact Backup

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35233
        • Recruiting
        • University of Alabama at Birmingham
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Self Identifies as Non-Hispanic Black
  • Between 16-49 years old
  • Pregnant individuals between 8⁰ - 22⁶ weeks gestational age
  • Live singleton or dichorionic twin gestation
  • Dating sonogram at <23 weeks gestation
  • Area Deprivation Index (ADI) National 4th or 5th Quintile
  • Planning to deliver at UAB Hospital
  • Speaks and writes in English
  • No indication for delivery at the time of enrollment

Exclusion Criteria:

  • Declines randomization
  • Speaks or writes in languages other than English
  • Currently incarcerated
  • Fetal demise diagnosed prior to enrollment
  • Known major structural chromosomal abnormalities prior to enrollment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Digital Health Intervention
This group will receive routine prenatal care services. Additionally, those randomized to this arm will receive a DHI intervention. A modified DHI will be utilized that was developed by Memora Health in conjunction with EQUATE partners at UPenn and feedback from the POPPY Study Team and Community Advisory Board. All content is designed for 7th grade Flesch-Kincaid level or lower.
Health care information delivered via a link in a text message that is then opened in a secure browser.
Other Names:
  • DHI
Experimental: Community health worker (CHW)
Individuals randomized to this group will receive routine prenatal care services. Additionally, they will receive a CHW intervention. The CHW intervention will be adapted from an ongoing CHW program in Jefferson County, AL called "From Day One (FDO)", a comprehensive patient-centered program designed to educate and provide non-clinical, psychosocial, emotional support to expectant mothers from the 1st trimester of pregnancy through their child's first year of life. The intervention has been modified by the POPPY Study Team and Community Advisory Board.
Health care information delivered via CHW.
Other Names:
  • CHW
Experimental: DHI Plus CHW
This group will receive routine prenatal care services. Additionally, this group will receive both DHI and CHW interventions.
Health care information delivered via DHI plus CHW
No Intervention: Usual Care
This group will receive routine prenatal care services.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participant acceptance of randomization arm / intervention
Time Frame: From randomization to 6 weeks postpartum

Participant acceptance is defined as a yes response to this question:

"I would recommend the care I received to someone in a similar situation."

From randomization to 6 weeks postpartum
Participant use of digital health and/or community health worker interventions
Time Frame: From randomization to 6 weeks postpartum
Use of the intervention for the digital health arm(s) is defined as the % of opened text messages. Use of the intervention for the community health worker arm(s) is defined as the % of planned sessions in which the participant engages with the community health worker.
From randomization to 6 weeks postpartum

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Outpatient Prenatal Care Visits
Time Frame: Duration of pregnancy through 6 weeks postpartum
Number of outpatient prenatal care and postpartum visits
Duration of pregnancy through 6 weeks postpartum
Preterm Birth
Time Frame: At birth
Delivery of a neonate at less than 37 weeks
At birth
Neonatal birthweight
Time Frame: At birth
Weight of neonate at birth
At birth
Cesarean delivery
Time Frame: At birth
Occurrence of a cesarean birth
At birth
Maternal blood transfusion
Time Frame: Duration of pregnancy through 6 weeks postpartum
Transfusion of blood products
Duration of pregnancy through 6 weeks postpartum
Breastfeeding intent
Time Frame: From randomization to delivery of the infant(s)
Participant's self-reported intent of whether or not to express breast milk upon admission to the delivery-associated hospitalization
From randomization to delivery of the infant(s)
Vaccination rate
Time Frame: Pregnancy through 6 weeks postpartum / 6 weeks of life
The number of recommended vaccinations for which the mother and newborn accepted
Pregnancy through 6 weeks postpartum / 6 weeks of life
Maternal postpartum readmission
Time Frame: From discharge from the delivery-associated hospitalization to 6 weeks postpartum
Admission of the mother to the hospital after discharge from the delivery-associated hospitalization
From discharge from the delivery-associated hospitalization to 6 weeks postpartum
Neonatal hospital readmission
Time Frame: Birth to 6 weeks of life
Admission of a neonate to the hospital after discharge from the hospital after birth
Birth to 6 weeks of life

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Rachel Sinkey, MD, University of Alabama at Birmingham

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 17, 2023

Primary Completion (Estimated)

June 30, 2024

Study Completion (Estimated)

January 31, 2025

Study Registration Dates

First Submitted

June 25, 2023

First Submitted That Met QC Criteria

July 3, 2023

First Posted (Actual)

July 11, 2023

Study Record Updates

Last Update Posted (Actual)

July 21, 2023

Last Update Submitted That Met QC Criteria

July 19, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 300009897

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pregnancy

Clinical Trials on Digital Health intervention

3
Subscribe